Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.

Authors
Type
Published Article
Journal
Investigational New Drugs
1573-0646
Publisher
Springer-Verlag
Publication Date
Volume
30
Issue
3
Pages
1116–1120
Identifiers
DOI: 10.1007/s10637-011-9671-z
PMID: 21509469
Source
Medline
License
Unknown

Abstract

The incidence of renal toxicity in phase I pts treated with antiangiogenic compounds was much higher than expected. Simple screening of Cr levels appears to be insufficient and careful nephrologic monitoring at baseline and during treatment should be implemented in early clinical trials assessing the risk/benefit ratio of new antiangiogenic compounds.

Statistics

Seen <100 times